Table 48.
Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC | NAL | CIP | AZM | COL | SMX | TMP | TET |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Austria | 154 | 4.5 | 8.4 | 31.8 | 0.6 | 0.6 | 0 | 0 | 16.9 | 22.7 | 0 | 0 | 18.2 | 11 | 40.9 |
France | 182 | 1.1 | 13.2 | 67 | 0.5 | 0.5 | 0 | 0 | 21.4 | 24.7 | 2.2 | 2.7 | 45.1 | 41.8 | 67.6 |
Germany | 188 | 6.4 | 16 | 63.3 | 2.1 | 1.6 | 0 | 0.5 | 22.3 | 32.4 | 2.1 | 9 | 30.3 | 22.3 | 43.1 |
Hungary | 170 | 2.9 | 18.2 | 50.6 | 1.2 | 1.2 | 0 | 0 | 48.2 | 67.1 | 3.5 | 0 | 30.6 | 24.1 | 64.1 |
Italy | 170 | 8.8 | 33.5 | 85.9 | 2.9 | 1.8 | 0 | 0 | 50 | 61.2 | 7.1 | 14.7 | 75.3 | 71.8 | 83.5 |
Poland | 171 | 7.6 | 20.5 | 77.8 | 0.6 | 0.6 | 0 | 0 | 50.3 | 70.8 | 0.6 | 4.7 | 47.4 | 39.8 | 67.8 |
Portugal | 171 | 15.2 | 55.6 | 84.8 | 2.9 | 2.9 | 0 | 0 | 77.8 | 83 | 4.7 | 25.1 | 74.9 | 56.1 | 88.3 |
Romania | 30 | 20 | 76.7 | 83.3 | 0 | 0 | 0 | 0 | 50 | 76.7 | 6.7 | 6.7 | 70 | 40 | 73.3 |
Spain | 169 | 8.9 | 35.5 | 82.8 | 16 | 16 | 0 | 0 | 56.8 | 66.3 | 3 | 3 | 55.6 | 35.5 | 82.2 |
Sweden | 85 | 0 | 0 | 8.2 | 0 | 0 | 0 | 0 | 1.2 | 1.2 | 0 | 0 | 5.9 | 3.5 | 16.5 |
United Kingdom | 224 | 2.2 | 7.6 | 60.7 | 0.4 | 0.4 | 0 | 0 | 14.3 | 15.6 | 0.9 | 0 | 25.4 | 22.8 | 67 |
Total (11 MSs) | 1,714 | 6.2 | 22.5 | 64.6 | 2.7 | 2.6 | 0 | 0.1 | 37.2 | 46.3 | 2.6 | 6.1 | 42.8 | 34.3 | 64.8 |
Norway | 156 | 1.3 | 0.6 | 12.8 | 0 | 0 | 0 | 0.6 | 0.6 | 1.3 | 0 | 0.6 | 10.9 | 3.2 | 8.3 |
ECOFFs: epidemiological cut‐off values; MSs: Member States; N: number of isolates tested; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.